Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Anna PecorelliBarbara LenziAnnagiulia GramenziFrancesca GarutiFabio FarinatiEdoardo G GianniniFrancesca CiccaresePiscaglia FabioGian Lodovico RapacciniMaria Di MarcoEugenio CaturelliMarco ZoliFranco BorzioRodolfo SaccoGiuseppe CabibboMartina FelderFilomena MoriscoAntonio GasbarriniGianluca Svegliati BaroniFrancesco G FoschiElisabetta BiasiniAlberto MasottoRoberto VirdoneMauro BernardiFranco Trevisaninull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2016)
In everyday practice TACE represents the first-line therapy in an half of patients with naïve BCLC-B HCC since treatment choice is driven not only by liver function and nodule characteristics, but also by contraindications to procedures, comorbidities, age and patient opinion. The treatment type is an independent prognostic factor in BCLC-B patients and curative options offer the best outcome.